3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
79
Carcinoma, Renal Cell
36
Neoplasms
35
Liver Neoplasms
22
Carcinoma, Non-Small-Cell Lung
7
Carcinoma
7
Neoplasm Metastasis
6
Melanoma
5
Thyroid Neoplasms
4
Kidney Neoplasms
4
Breast Neoplasms
3
Financial Stress
2
Vaccinia
1
Stomach Neoplasms
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoma
1
Lung Neoplasms
1
Liver Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Insulin-Like Growth Factor I, Resistance To
1
Hypophosphatemia
1
Hepatitis C
1
Hepatitis B
1
Glioblastoma
1
Digestive System Neoplasms
1
Interventions
peginterferon alfa-2a
1
menatetrenone
1
lenvatinib
1
human papillomavirus vaccine, L1 type 16, 18
1
Tenofovir
1
Sorafenib
1
PHY 906
1
Engerix-B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hepatitis B
×
Sorafenib
×
Clear all
NCT04710641
2025-03-06
OUTREACH2
Mina Alpha Limited
Phase 2
Completed
8 enrolled